Month: April 2018

Scientists identify a potential treatment for Hereditary Hemorrhagic Telangiectasia

Collaboration between basic and clinical research groups at Bellvitge leads to the first therapy for this disease The work of researchers Francesc Viñals and Mariona Graupera at the Bellvitge Biomedical Research Institute (IDIBELL, Oncobell program) – Catalan Institute of Oncology (ICO, ProCURE program) – University of Barcelona, ​​together with Dr. Antoni Riera-Mestre (IDIBELL, Bellvitge University …

Scientists identify a potential treatment for Hereditary Hemorrhagic Telangiectasia Read More »

The EPICUP Project receives a Pfizer Foundation Innovation award

The development of the EPICUP epigenomic tool, capable of improving the diagnosis of metastases of unknown origin, has been awarded the Prize for Scientific Innovation in its Clinical Research modality by the Pfizer Foundation, which was given to the first author of the study, Dr. Sebastian Morán, at an event held at the Hospital la …

The EPICUP Project receives a Pfizer Foundation Innovation award Read More »

Bringing research closer to the industry

IDIBELL celebrates the first edition of its Accelerator Meeting Point The Bellvitge Biomedical Research Institute (IDIBELL) held yesterday April 16th the first edition of its Accelerator Meeting Point, a meeting where CataloniaBio -association of biomedicine and health companies in Catalonia-, Biocat -institution responsible for the promotion of the life sciences and health sector in Catalonia- …

Bringing research closer to the industry Read More »

IDIBELL redefines itself in its annual Retreat

On April 13th and 14th, IDIBELL held its annual scientific retreat at the Bellvitge Cultural Center. During two days that were attended by more than 150 people between group leaders, principal investigators and external collaborators, IDIBELL presented its research programs and gave the firing shot to the preparation of the new Strategic Plan 2018-2021. The …

IDIBELL redefines itself in its annual Retreat Read More »

€ 40,000 to move forward developing therapies against MPNST

The group of Dr. Conxi Lázaro, principal investigator of the Hereditary cancer research group of the Oncobell program (IDIBELL) and head of the Molecular Diagnostic Unit of the Hereditary Cancer Program (ICO), has received one of the Neurofibromatosis Research Grants of the Neurofibromatosis Proyecto Foundation in its Call 2018. The two-year grant, worth € 40,000, …

€ 40,000 to move forward developing therapies against MPNST Read More »

Researchers describe the in vivo cooperation of the basolateral transporters LAT2 / CD98hc and TAT1 in the renal reabsorption of neutral amino acids

Researchers led by Dr. Virginia Nunes (IDIBELL, UB, CiBERER U730) and Dr. Manuel Palacín (IRBB, UB, CIBERER U731) have demonstrated, for the first time, in vivocooperation of two basolateral transporters of neutral amino acids and their involvement in the renal reabsorption of these amino acids. The work, published in the Journal of the American Society of Nephrology (JASN), …

Researchers describe the in vivo cooperation of the basolateral transporters LAT2 / CD98hc and TAT1 in the renal reabsorption of neutral amino acids Read More »

A potential new therapeutic target for Ewing sarcoma

The Oncobell sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, has identified a potential new therapeutic target for Ewing sarcoma, the second most frequent bone cancer in children and adolescents, and a tumor known by its aggressiveness and tendency to metastasize. The research, published in International Journal of Cancer, has …

A potential new therapeutic target for Ewing sarcoma Read More »

Scroll to Top